BioSpace News Archive

Drug Development

Will GSK/Tesaro’s Checkpoint Inhibitor Be Able to Compete With Merck’s Keytruda?

Only a few months after GlaxoSmithKline acquired Waltham, Mass.-based Tesaro, Tesaro released promising data from its Phase I/II GARNET study of dostarlimab in endometrial cancer.

March 20, 2019
·
3 min read
·
Mark Terry
Business

More Ovarian Cancer Woes for Merck KGaA and Pfizer as They Halt Late-Stage Trial

The trial, which paired a checkpoint inhibitor and PARP inhibitor, was not likely to hit endpoints. It was the second ovarian cancer trial failure for the two companies in six months.

March 20, 2019
·
2 min read
·
Alex Keown
Business

Flagship Pioneering Closes $824 Million Fund to Support Companies in Its Cambridge Lab

Flagship Pioneering closed out a monster pool of funds to support a number of pioneering life science companies. Cambridge, Mass.-based Flagship secured $824 million in a new capital pool to boost companies that launch from its Flagship Labs incubator unit.

March 20, 2019
·
2 min read
·
Alex Keown
Drug Development

MorphoSys and I-Mab Biopharma Announce Initiation of Pivotal Phase 2 Study of TJ202/MOR202 for Multiple Myeloma

MorphoSys AG andI-Mab Biopharma announced that the first patient has been dosed in a phase 2 clinical study in Taiwan to evaluate MorphoSys’s investigational human CD38 antibody TJ202/MOR202 in patients with relapsed or refractory multiple myeloma.

March 20, 2019
·
8 min read
Business

SCRS Announces SPRIA Europe Winner

The Society for Clinical Research Sites announced to attendees at its 2019 European Site Solutions Summit that SCALA Clinical Research is the winner of the European Site Patient Recruitment Innovation Award.

March 20, 2019
·
2 min read
Deals

Galapagos increases share capital through warrant exercises on 20 March 2019

Galapagos NV announces a share capital increase arising from warrant exercises.

March 20, 2019
·
2 min read
Drug Development

Sage Wins FDA Approval for ‘Game-Changing’ Postpartum Depression Treatment

The approval of Zulresso marks the first and only treatment for postpartum depression (PPD) approved by the U.S. Food and Drug Administration.

March 20, 2019
·
2 min read
·
Alex Keown
Business

BioSpace’s Global Biopharma Roundup: March 21

Biotech and pharma companies from across Europe and Asia provide updates on pipeline and business activities.

March 20, 2019
·
6 min read
·
Alex Keown
Business

Alexion Inks Two Partnerships: Affibody AB and Zealand Pharma

Alexion Pharmaceuticals announced two big collaboration partnerships today. First, Alexion, headquartered in Boston, and Affibody AB, located in Solna, Sweden, signed a partnership deal to co-develop ABY-039 for Immunoglobulin G (IgG)-mediated autoimmune diseases.

March 20, 2019
·
3 min read
·
Mark Terry
BioMidwest

7 Drugs Expected to Be Blockbusters by 2023

A new market research report by Clarivate Analytics, “Cortellis Drugs to Watch,” identified seven new drugs it believes will hit sales of $1 billion or more, the so-called “blockbuster” mark, by 2023.

March 20, 2019
·
5 min read
·
Mark Terry